Common Stock, $0.0001 par value per share

CAMP4 THERAPEUTICS CORPORATION

One Kendall Square, Cambridge, MA, 02139

Rows 11 and 13 of each Reporting Entities' cover page to this Schedule 13D/A set forth the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by such Reporting Entity and are incorporated by reference. The percentage set forth in each row 13 is based upon 51,919,321 shares of Common Stock outstanding as of March 4, 2026, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on March 5, 2026. Everest LP directly holds 2,495,562 shares of Common Stock. Enavate GP is the general partner of Everest LP and shares voting and investment authority over the shares held by Everest LP.

Rows 7 through 10 of each Reporting Entities' cover page to this Schedule 13D/A set forth the number of shares of Common Stock as to which such Reporting Entity has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.

Except as set forth below, none of the Reporting Entities has effected any transactions with respect to the securities of the Issuer during the past sixty days. On January 12, 2026, Everest LP sold an aggregate of 497 shares in open market transactions at prices ranging from $6.05 to $6.20 (weighted average sales price of $6.11 per share). On January 14, 2026, Everest LP sold an aggregate of 11,228 shares in open market transactions at prices ranging from $6.00 to $6.05 (weighted average sales price of $6.00 per share). On February 25, 2026, Everest LP sold an aggregate of 7,561 shares in open market transactions at prices ranging from $4.50 to $4.62 (weighted average sales price of $4.59 per share). On February 26, 2026, Everest LP sold an aggregate of 5,413 shares in open market transactions at prices ranging from $4.50 to $4.63 (weighted average sales price of $4.54 per share). On February 27, 2026, Everest LP sold an aggregate of 2,395 shares in open market transactions at prices ranging from $4.50 to $4.72 (weighted average sales price of $4.63 per share). On March 2, 2026, Everest LP sold an aggregate of 6,926 shares in open market transactions at prices ranging from $4.50 to $4.63 (weighted average sales price of $4.52 per share). On March 9, 2026, Everest LP sold an aggregate of 91,699 shares in open market transactions at prices ranging from $6.50 to $7.15 (weighted average sales price of $6.69 per share). On March 10, 2026, Everest LP sold an aggregate of 99,639 shares in open market transactions at prices ranging from $5.55 to $6.35 (weighted average sales price of $5.83 per share).

No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the Common Stock.

The Reporting Persons ceased to be the beneficial owners of more than five percent of the Common Stock on March 9, 2026.